It has been known for many years that buprenorphine binds to at high affinity and antagonizes the KOR, and a variety of research has demonstrated its efficacy in the management of depressive and anxious symptomatology, even in patients refractory to conventional antidepressants and to electroconvulsive therapy.
It has been known for decades that buprenorphine binds to at high affinity and antagonizes the KOR. In addition, there have been many reports over the years supporting the idea of it being effective in the management of depressive and anxious symptomatology, and two small clinical trials have shown it to produce remission even in depressive patients refractory to conventional antidepressants and electroconvulsive therapy.